Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
NOVARTIS NEW ZEALAND LIMITED,Voretigene neparvovec,"inherited retinal dystrophy, biallelic RPE65 mutations",Voretigene neparvovec (LUXTURNA),Options for investment,Hospital,Sensory Organs
